High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients

References

• Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors [The Prospective Pravastatin Pooling Project]. Circulation 2000;102:1893–900
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Olsson AJ, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046–51
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. New Engl J Med 2004;350:1495–504
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253–68
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004;291:1701–80
   Google Scholar
• Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187–95
   PubMed Web of Science ®Google Scholar
• Ijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650–8
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11–S20
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17: 107–13
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52
   PubMed Web of Science ®Google Scholar
• Brown BG. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J 2005;7(Suppl):F34–F40
   Google Scholar
• Kastelein JJP. The realities of dyslipidaemia: what do the studies tell us? Eur Heart J 2005;7(Suppl):F27–F33
   Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with nicotinic acid. J Am Coll Cardiol 1986;8:1245–55
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and nicotinic acid in coronary heart disease. J Am Med Assoc 1975;231:360–81
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group]. New Engl J Med 1999;341:410–8
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment changes in risk factors, and incidence of coronary heart disease. New Engl J Med 1987;317:1237–45
   Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356–9
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice [Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. Eur Heart J 2003;24:1601–10
   Google Scholar
• Anon. AFSSAPS: prise en charge thérapeutique du subject dyslipidémique: available from www.afssaps.sante.fr [last accessed March 2005]
   Google Scholar
• Anon. Prodigy guidance hyperlipidaemia. Available at www.prodigy. nhs.uk/guidance; UK update April 2005 [last accessed May 2005]
   Google Scholar
• Balkau B, Charles MA, Drivsholm T, et al.; European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364–76
   Google Scholar
• Devroey D, Velkeniers B, Betz W, Kartounian J. The prevalence of low levels of HDL-cholesterol among patients treated with lipid-lowering drugs. Br J Cardiol 2003;10:50–5
   Google Scholar
• Bruckert E, Pamphile R, Mc Coy F, André P. Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients. Eur Heart J 2005;7(Suppl):F23–F26
   Google Scholar
• Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10(Suppl):S1–S10
   Google Scholar
• Adult Treatment Panel III. National cholesterol education program. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [National Institutes of Health/National Heart Lung and Blood Institute]. Available at www.nhlbi.nih.gov/guidelines/cholesterol [last accessed July 2005]
   Google Scholar
• International Diabetes Federation. IDF worldwide definition of the metabolic syndrome. Available at www.idf.org [last accessed July 2005]
   Google Scholar
• Genest Jr J, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792–802
   PubMed Web of Science ®Google Scholar
• Lamarche B, Despres JP, Moorjani S, et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec cardiovascular study. Atherosclerosis 1996;119:235–45
   PubMed Web of Science ®Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J Am Med Assoc 1999;282:2340–6
   Google Scholar
• Goldberg A, Alagona Jr P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100–5
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J 2005;7(Suppl):F56–F62
   Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185–97
   PubMed Web of Science ®Google Scholar
• Gotto Jr AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004;43:717–24
   PubMed Web of Science ®Google Scholar